Literature DB >> 32029901

MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer.

Xin Tong1,2, Shengjie Wang1,2,3, Zhe Lei1,2, Chang Li4, Cuijuan Zhang1,2, Zhiyue Su1,2, Xia Liu1,2, Jun Zhao4, Hong-Tao Zhang5,6,7.   

Abstract

Myocardin (MYOCD) promotes Smad3-mediated transforming growth factor-β (TGF-β) signaling in mouse fibroblast cells. Our previous studies show that TGF-β/SMADs signaling activation enhances epithelial-mesenchymal transition (EMT) in human non-small cell lung cancer (NSCLC) cells. However, whether and how MYOCD contributes to TGF-β-induced EMT of NSCLC cells are poorly elucidated. Here, we found that TGF-β-induced EMT was accompanied by increased MYOCD expression. Interestingly, MYOCD overexpression augmented EMT and invasion of NSCLC cells induced by TGF-β, whereas knockdown of MYOCD expression attenuated these effects. Overexpression and knockdown of MYOCD resulted in the upregulation and downregulation of TGF-β-induced Snail mRNA, respectively. Moreover, MYOCD overexpression promoted TGF-β-stimulated NSCLC cell metastasis in vivo. MYOCD was highly expressed and positively correlated with Snail in metastatic NSCLC tissues. Mechanistically, MYOCD directly interacted with SMAD3 and sustained the formation of TGF-β-induced nuclear SMAD3/SMAD4 complex, facilitating TGF-β/SMAD3-induced transactivation of Snail. Importantly, MYOCD was transcriptionally activated by TGF-β-induced SMAD3/SMAD4 complex and CRISPR/Cas9-mediated silencing of SMAD3/SMAD4 led to a reduction in MYOCD mRNA expression. Taken together, our findings indicate that MYOCD promotes TGF-β-induced EMT and metastasis of NSCLC and identify a positive feedback loop between MYOCD and SMAD3/SMAD4 driving TGF-β-induced EMT.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32029901     DOI: 10.1038/s41388-020-1189-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  49 in total

Review 1.  Cancer metastasis: building a framework.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.

Authors:  L Wang; H Yang; Z Lei; J Zhao; Y Chen; P Chen; C Li; Y Zeng; Z Liu; X Liu; H-T Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  TGF-β-activated SMAD3/4 complex transcriptionally upregulates N-cadherin expression in non-small cell lung cancer.

Authors:  Haiping Yang; Longqiang Wang; Jun Zhao; Yongbing Chen; Zhe Lei; Xia Liu; Wei Xia; Lingling Guo; Hong-Tao Zhang
Journal:  Lung Cancer       Date:  2015-01-05       Impact factor: 5.705

Review 6.  Epithelial-mesenchymal transitions: twist in development and metastasis.

Authors:  Yibin Kang; Joan Massagué
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

7.  JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells.

Authors:  Reng-Yun Liu; Yuanyuan Zeng; Zhe Lei; Longqiang Wang; Haiping Yang; Zeyi Liu; Jun Zhao; Hong-Tao Zhang
Journal:  Int J Oncol       Date:  2014-02-21       Impact factor: 5.650

Review 8.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

Review 9.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

10.  Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

Authors:  Paul A Bunn; Nick Thatcher
Journal:  Oncologist       Date:  2008
View more
  14 in total

1.  Pseudogene MSTO2P Interacts with miR-128-3p to Regulate Coptisine Sensitivity of Non-Small-Cell Lung Cancer (NSCLC) through TGF-β Signaling and VEGFC.

Authors:  Minwei Gu; Xinlian Wang
Journal:  J Oncol       Date:  2022-06-26       Impact factor: 4.501

2.  Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer.

Authors:  Alice Bradfield; Lucy Button; Josephine Drury; Daniel C Green; Christopher J Hill; Dharani K Hapangama
Journal:  Methods Protoc       Date:  2020-09-03

Review 3.  Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.

Authors:  Lu Huang; Zhi Liao; Zhixi Liu; Yan Chen; Tingwenli Huang; Hongtao Xiao
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

4.  Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer.

Authors:  Qian Zhou; Wensheng Chen; Zhenzhen Fan; Zhipeng Chen; Jinxia Liang; Guandi Zeng; Lu Liu; Wanting Liu; Tong Yang; Xin Cao; Biao Yu; Meng Xu; Ye-Guang Chen; Liang Chen
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

5.  Quaking 5 suppresses TGF-β-induced EMT and cell invasion in lung adenocarcinoma.

Authors:  Shengjie Wang; Xin Tong; Chang Li; Ersuo Jin; Zhiyue Su; Zelong Sun; Weiwei Zhang; Zhe Lei; Hong-Tao Zhang
Journal:  EMBO Rep       Date:  2021-03-26       Impact factor: 8.807

6.  Cooperative participation of epigenomic and genomic alterations in the clinicopathological diversity of gastric adenocarcinomas: significance of cell adhesion and epithelial-mesenchymal transition-related signaling pathways.

Authors:  Menghan Yang; Eri Arai; Yoriko Takahashi; Hirohiko Totsuka; Suenori Chiku; Hirokazu Taniguchi; Hitoshi Katai; Hiromi Sakamoto; Teruhiko Yoshida; Yae Kanai
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

Review 7.  SNAIL1: Linking Tumor Metastasis to Immune Evasion.

Authors:  Xiaolong Tang; Xue Sui; Liang Weng; Yongshuo Liu
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

8.  RAB26 contributes to the progression of non-small cell lung cancer after being transcriptionally activated by SMAD3.

Authors:  Haixia Ren; Bo Yang; Mingjiang Li; Chunling Lu; Xiaoping Li
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 9.  Cancer drug resistance induced by EMT: novel therapeutic strategies.

Authors:  Javier De Las Rivas; Anamaria Brozovic; Sivan Izraely; Alba Casas-Pais; Isaac P Witz; Angélica Figueroa
Journal:  Arch Toxicol       Date:  2021-05-18       Impact factor: 5.153

10.  hiPSC Modeling of Lineage-Specific Smooth Muscle Cell Defects Caused by TGFBR1A230T Variant, and Its Therapeutic Implications for Loeys-Dietz Syndrome.

Authors:  Dong Zhou; Hao Feng; Ying Yang; Tingting Huang; Ping Qiu; Chengxin Zhang; Timothy R Olsen; Jifeng Zhang; Y Eugene Chen; Dogukan Mizrak; Bo Yang
Journal:  Circulation       Date:  2021-08-04       Impact factor: 39.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.